MedPage Today on MSN
Risky drugs still in the mix for dementia patients
CNS-active drugs are associated with an increased risk of falls, delirium, and hospitalization. They are often prescribed for ...
Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as ...
Zidovudine PBCA and MMA-SPM Emulsion polymerization and free-radical polymerization PBCA as a carrier; alcohol increases permeability of BMVECs to NPs [114] Indinavir Drug nanocrystals and lipoid E80 ...
Healthcare Asia Magazine on MSN
CNS drug market to hit $235.9b by 2033 as neurological diseases surge
Mergers and licensing deals are accelerating as the global market valuation nears quarter-trillion mark. The global market ...
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback